Drug intelligence / Profile preview

secnidazole

Development stage
Approved
Lead developer
Lupin
Modality
Small Molecules
Administration
Oral
01

Overview

Secnidazole is a nitroimidazole antimicrobial agent used primarily to treat bacterial vaginosis and trichomoniasis in patients 12 years of age and older. It is a broad-spectrum antibiotic effective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa such as *Trichomonas vaginalis*, *Entamoeba histolytica*, and *Giardia lamblia*. The drug acts by entering the target pathogen where its nitro group is reduced by microbial nitroreductase enzymes to generate reactive intermediates that damage DNA helix structure, disrupt protein synthesis and replication, leading to cell death. Secnidazole is administered orally (typically as granules) in a single dose regimen.

Brand names
SolosecFlagentylSindoseSecnil
02

Targets

NeuraminidaseBacterial Ribosome

Beyond the preview

Go deeper on secnidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on secnidazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call